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Abstract
Background Although adding a drug to an emergency
department-based automated medication management sys-
tem is known to increase how frequently it is ordered, little
is known about this effect when the added drug does not
offer substantial benefit over a substitute drug that was
already available.
Aims We studied the effect of adding nebulized levalbuterol
to a pediatric emergency department-based automated medi-
cation management system that already included albuterol.
Methods All completed orders for nebulized levalbuterol or
nebulized albuterol from our academic pediatric emergency
department were retrospectively identified using a com-
puterized pharmacy database. We compared ordering of
these drugs for the year before levalbuterol was added to the
automated medication management system, during which it
was available only from the hospital central pharmacy via a
pneumatic tube system, with the year following its inclusion
in the system.
Results There were 6 orders for nebulized levalbuterol and
1,295 orders for nebulized albuterol during the year that
levalbuterol was only available from the hospital central
pharmacy, and 7 orders for nebulized levalbuterol and 1,108
orders for nebulized albuterol during the year following
levalbuterol’s inclusion in the automated medication man-
agement system. There was no significant difference
(p=0.78).
Conclusions Use of nebulized levalbuterol, in relation to
that ofnebulizedalbuterol,for whichitisasubstitute,didnot
significantly change when it was included in the pediatric
emergency department automated medication management
system. This may reflect the lack of substantial benefit that
levalbuterol offers over nebulized albuterol in managing
children in the emergency department.
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Introduction
Many emergency departments use computerized, automated
medicationmanagementsystemstomanagetheiron-sitedrug
inventories.Thesesystemsaremeanttoimprovedrugstorage
security, reduce dosing errors, and improve charge capture,
among other features. Little is known about the effects of
emergencydepartment-basedautomatedmedication manage-
ment systems on emergency provider prescribing patterns.
This includes uncertainty about the effects on drug ordering
of adding a drug to a previously established automated
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adding drugs that were previously available to an emergency
department only from a hospital central pharmacy to such an
emergency department system resulted in substantial
increases in their use [1]. This suggested that, in the fast-
paced emergency department setting, making a drug more
rapidly accessible influenced emergency practitioners to
order itmore frequently.Thepresence ofthis effect,however,
has not been studied for drugs added to an automated
medication management system that did not offer substantial
benefit (e.g.,lower cost, fewer side effects,higher therapeutic
efficacy) over a substitute drug already available via the
system.
Nebulizedlevalbuterol,asubstitutefornebulizedalbuterol,
has been shown to provide little, if any, additional benefit
over nebulized albuterol in managing children in the emer-
gency department, despite adding additional cost [2–6].
Levalbuterol for nebulization was recently added to our
pediatric emergency department’s automated medication
management system, having previously been available only
through the hospital central pharmacy. Since albuterol had
already been available for several years in our pediatric
emergency department’s automated medication management
system, the addition of levalbuterol provided a “natural
experiment” through which we could study the effect, if any,
that adding levalbuterol for nebulization to the pediatric
emergency department automated medication management
system had on its pediatric emergency department use, in
relation to albuterol use. As suggested by previous research
[1], we hypothesized that the addition of levalbuterol would
be associated with a change in the use of levalbuterol as a
substitute for albuterol, compared with the period during
which it was available exclusively via the less convenient
hospital central pharmacy.
Materials and methods
Study design and setting
We conducted a retrospective observational study using a
preexisting computerized pharmacy database of a large,
urban, academic university hospital to identify all completed
orders for either nebulized albuterol or levalbuterol for
pediatric emergency department patients (age ≤18) during
the study period.
The pediatric emergency department treats over 26,000
pediatric patients annually in a dedicated pediatric emer-
gency department next to an adult emergency department.
The large majority are treated by a combination of resident,
fellow, or nurse practitioner and attending physicians;
occasionally, minimally acute patients may be seen by a
nurse practitioner alone. The hospital has a large formulary
of available medications, a fraction of which is available in
a frequently used, on-site automated medication manage-
ment system (Pyxis Medstation™) that is conveniently
located in the pediatric emergency department. Selection of
medications for inclusion in this system is at the discretion
of the hospital Pharmacy Department. Medications are
dispensed either from the hospital central pharmacy, typi-
cally via a pneumatic tube system, or directly from the on-
site automated medication management system. In our
pediatric emergency department, nurses may obtain medi-
cations readily and simply from the automated medication
management system; obtaining medications via the hospital
central pharmacy requires several additional steps and
significantly more time. The computerized pharmacy data-
base includes prospectively collected data on all completed
orders for medications dispensed to patients in the pediatric
emergency department, from either source, but does not
include information regarding the ordering provider.
Levalbuterol for nebulization was added to our pediatric
emergency department’s automated medication manage-
ment system in December 2005, having previously been
available only through the hospital central pharmacy.
Albuterol for nebulization had been and continued to be
available from the pediatric emergency department auto-
mated medication management system during the entire
study period. The 2-year study period (from December
2004 through December 2006) consisted of the year before
and the year after levalbuterol for nebulization was added to
the pediatric emergency department’s automated medica-
tion management system. During the first year, levalbuterol
for nebulization was available to pediatric emergency
department patients only from the hospital central pharmacy
via pneumatic tube. During the second year,levalbuterol was
available either through the automated medication manage-
ment system or the hospital central pharmacy. Levalbuterol
metered-dose inhalers were not on the hospital formulary
during the study period. Albuterol was available from the
automated medication management system in both for
nebulization and metered-dose inhaler form during the entire
study period. We compared only the use of albuterol for
nebulization to use of levalbuterol for nebulization for this
study. The inclusion of levalbuterol to the pediatric emer-
gency department’s automated medication management
system was widely publicized among the pediatric emer-
gency department’s physician, nurse practitioner, and
nursing staff by the emergency department lead pharmacist,
who added the drug to the emergency department system at
the request of an individual pediatric emergency department
attending physician. Comparative information on drug
efficacy, costs, etc. was not specifically distributed. There
were no changes in hospital protocol regarding management
of acute asthma in children during the study period. As
this study had not yet been conceived during the study
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aspects.
Outcome measure and data analysis
We compared the number of completed orders for nebulized
levalbuterolandfornebulizedalbuterolinthefirstyearofthe
study period, during which levalbuterol was available for
treatment of pediatric emergency department patients only
via the hospital central pharmacy, to the same numbers in the
following year, during which levalbuterol was available both
from the pediatric emergency department’s automated
medication management system and from the hospital
central pharmacy. Data about medication order completion
and patient ages were obtained directly from the computer-
ized hospital pharmacy database; no other patient-specific
records were reviewed. We compared the numbers of
completed orders with the chi-square test with Yates’ correc-
tion for continuity.
Our institution’s Research Subjects Review Board
exempted this study.
Results
During the first year of the study period, there were 6
completed orders for nebulized levalbuterol and 1,295 for
nebulized albuterol. During the second year, there were 7
completed orders for nebulized levalbuterol and 1,108 for
nebulized albuterol. We treated a total of 27,754 children in
the pediatric emergency department during the first study
year and 26,151 children during its second year. Use of
nebulized levalbuterol and albuterol were not statistically
significantly different between the 2 years (Yates’ correc-
tion chi-square = 0.078; p=0.78). Of interest, the physician
who requested the addition of levalbuterol remained on the
faculty during the entire study period.
Discussion
Use of nebulized levalbuterol, in relation to that of
nebulized albuterol, for which it is a substitute, did not
significantly change when it was included in the pediatric
emergency department automated medication management
system. Previous research has demonstrated that adding
drugs to an emergency department automated medication
management system was associated with increased drug
ordering [1]. Levalbuterol use may not have increased
because levalbuterol offers little, if any, additional benefit
over nebulized albuterol in managing children in the
pediatric emergency department [2–6]. This would suggest
that, while readier access to drugs is an important factor in
their selection for use, emergency providers also consider
relative benefit when making drug choices.
This study has certain limitations. Although we relied on
the accuracy of existing computerized pharmacy records for
data on drug use, these records are well maintained at our
hospital. Albuterol was available for nebulization from a
multi-dose vial during the study period; repeated doses,
therefore, could have missed being recorded in the com-
puterized pharmacy record. Levalbuterol, however, was
available exclusively in single-dose containers, requiring
individualretrieval from ourcomputerizedsystem.Although
news of the availability of levalbuterol in the automated
medication management system was widely distributed, it
could potentially have escaped the notice of some of our
providers. A paper-based set of “standing orders” for
management of acute asthma in our pediatric emergency
department was available during the study period; as these
orders included nebulized albuterol but not levalbuterol, this
may have biased physicians away from levalbuterol use.
However, use of this order page is not required, and it is
commonly either not used or altered when the treating
provider deems it appropriate. Further, we did not limit our
study to patients with asthma, since either albuterol or
levalbuterol may be similarly administered to children who
are wheezing without a specific asthma diagnosis. Finally,
our before-after study design is subject to bias due to a
potential environmental or practice change between the two
time periods being compared; we are, however, aware of no
such relevant changes.
Conclusion
This study adds an important new facet to the understanding
of how the presence of an automated medication manage-
ment system can affect emergency physician ordering
practice. Previous work suggested that readier drug avail-
ability via an automated medication management system in
itself led to increased use of that drug [1]. This study
suggests that lack of advantage over a previously available
substitute drug may negate that increase. However, given
this study’s limitations, we suggest prospective validation
of these findings.
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